FDA Approves Livsayis, First siRNA Therapy for Generalized Myasthenia Gravis
REGN sits 59% above its 52-week low of $591.52.
Summary
The FDA approved Livsayis (cemdisiran), making it the first and only siRNA therapy for generalized myasthenia gravis and the only gMG treatment dosed subcutaneously four times a year. That dosing schedule is the commercial hook — it undercuts the frequent-infusion and daily-oral regimens patients currently face in a chronic neuromuscular disease. Regeneron will sell it only through a Livsayis REMS program, which adds distribution friction but is common for biologics of this type. The approval lands on top of a strong run: Q3 revenue grew 36% to $5.1 billion with record Dupixent sales, and the October Sanofi amendment added four antibodies to the pipeline. No launch timing, pricing, or peak-sales guidance was disclosed in the release.
At the time of this announcement, REGN was trading at $942.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $97.8B. The 52-week trading range was $591.52 to $991.73. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.